Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
Bottom Line: In univariate analysis, expression of cyclin A, Neu, Ki-67 index, and lack of OR expression were significantly associated with worse prognosis.When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with hazard ratios of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151).Overexpression of cyclin A was found in 86 out of the 201 OR-positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio 2.024, P=0.0462).
Affiliation: Division of Tumour Biology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: Cyclin A overexpression was significantly associated with overexpression of Neu, Ki-67, with expression of p53, with absence of OR, with high histological grade and high T-classification. Altogether, these associations suggest that overexpression of cyclin A is more frequently found in large size, undifferentiated, OR-negative breast tumours with an increased proliferative fraction. A representative cyclin A staining in breast cancer cells is given in Figure 3Figure 3
Affiliation: Division of Tumour Biology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. email@example.com